Literature DB >> 27549150

Accuracy of SWI sequences compared to T2*-weighted gradient echo sequences in the detection of cerebral cavernous malformations in the familial form.

Gianvincenzo Sparacia1, Claudia Speciale2, Aurelia Banco2, Francesco Bencivinni2, Massimo Midiri2.   

Abstract

PURPOSE: The purpose of this study was to assess the accuracy of susceptibility-weighted imaging (SWI), compared with T2*-weighted gradient echo (GRE) imaging in assessing cerebral cavernous malformations.
MATERIALS AND METHODS: We retrospectively evaluated 21 patients with a familial form of cavernous malformation. Magnetic resonance (MR) protocol included non-enhanced and contrast-enhanced fast-spin echo (FSE) T1-weighted sequences, FSE T2-weighted sequences, fluid-attenuated inversion-recovery (FLAIR), GRE T2*-weighted and SWI sequences. Images were reviewed in consensus by two expert neuroradiologists to assess the location, number, size and conspicuity of the lesions on T2*-weighted GRE and SWI sequences. Statistical differences in the number, size and conspicuity of the lesions seen on the SWI images and the T2*-weighted GRE images were assessed with the nonparametric Wilcoxon signed rank test.
RESULTS: The number of cavernous malformations was significantly higher (p < .001) on the SWI images (n = 152) than on T2*-weighted GRE images (n = 56). Lesion size was significantly higher (p < .001) on SWI images (mean: 0.4 cm, SD ± 0.55) than on T2*-weighted GRE sequences (mean: 0.2 cm, SD ± 0.51) and the differences were statistically significant (p < .001). Lesion conspicuity was significant higher (p < .001) on SWI than on T2*-weighted GRE images. In one patient who underwent a 2-month follow-up for the onset of neurologic symptoms related to cerebral hemorrhage, a cerebral hematoma was identified at the site of a cerebral cavernous malformation that was demonstrated only on the SWI images in the previous MR examination.
CONCLUSIONS: The SWI sequence, being more sensitive to substances which distort the local magnetic field than the GRE T2*W sequence, showed a higher sensitivity in identifying cerebral cavernous malformations. Thus, routine clinical neuroimaging protocol should contain SWI sequences to evaluate patients with (or suspected) cerebral cavernous malformations.
© The Author(s) 2016.

Entities:  

Keywords:  Cerebral cavernous malformation; T2*-weighted gradient echo sequence; diagnosis; imaging; susceptibility-weighted imaging

Mesh:

Year:  2016        PMID: 27549150      PMCID: PMC5033099          DOI: 10.1177/1971400916665376

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  26 in total

1.  Familial form of intracranial cavernous angioma: MR imaging findings in 51 families. French Society of Neurosurgery.

Authors:  L Brunereau; P Labauge; E Tournier-Lasserve; S Laberge; C Levy; J P Houtteville
Journal:  Radiology       Date:  2000-01       Impact factor: 11.105

2.  The value of susceptibility weighted magnetic resonance imaging in evaluation of patients with familial cerebral cavernous angioma.

Authors:  Haci Taner Bulut; Mehmet Akif Sarica; Ali Haydar Baykan
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  The natural history of familial cerebral cavernomas: a retrospective MRI study of 40 patients.

Authors:  P Labauge; L Brunereau; C Lévy; S Laberge; J P Houtteville
Journal:  Neuroradiology       Date:  2000-05       Impact factor: 2.804

4.  Cerebral cavernous malformations. Incidence and familial occurrence.

Authors:  D Rigamonti; M N Hadley; B P Drayer; P C Johnson; K Hoenig-Rigamonti; J T Knight; R F Spetzler
Journal:  N Engl J Med       Date:  1988-08-11       Impact factor: 91.245

5.  Prospective follow-up of 33 asymptomatic patients with familial cerebral cavernous malformations.

Authors:  P Labauge; L Brunereau; S Laberge; J P Houtteville
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

6.  Value of gradient-echo magnetic resonance imaging in the diagnosis of familial cerebral cavernous malformation.

Authors:  Fritz-Georg Lehnhardt; Ulrich von Smekal; Benedikt Rückriem; Werner Stenzel; Michael Neveling; Wolf-Dieter Heiss; Andreas H Jacobs
Journal:  Arch Neurol       Date:  2005-04

7.  The natural history of cavernous malformations: a prospective study of 68 patients

Authors: 
Journal:  Neurosurgery       Date:  1999-06       Impact factor: 4.654

Review 8.  Susceptibility-weighted imaging for differential diagnosis of cerebral vascular pathology: a pictorial review.

Authors:  Yu-Kun Tsui; Fong Y Tsai; Anton N Hasso; Fred Greensite; Binh V Nguyen
Journal:  J Neurol Sci       Date:  2009-09-20       Impact factor: 3.181

9.  Mutations within the MGC4607 gene cause cerebral cavernous malformations.

Authors:  C Denier; S Goutagny; P Labauge; V Krivosic; M Arnoult; A Cousin; A L Benabid; J Comoy; P Frerebeau; B Gilbert; J P Houtteville; M Jan; F Lapierre; H Loiseau; P Menei; P Mercier; J J Moreau; A Nivelon-Chevallier; F Parker; A M Redondo; J M Scarabin; M Tremoulet; M Zerah; J Maciazek; E Tournier-Lasserve
Journal:  Am J Hum Genet       Date:  2004-01-22       Impact factor: 11.025

10.  The natural history of familial cavernous malformations: results of an ongoing study.

Authors:  J M Zabramski; T M Wascher; R F Spetzler; B Johnson; J Golfinos; B P Drayer; B Brown; D Rigamonti; G Brown
Journal:  J Neurosurg       Date:  1994-03       Impact factor: 5.115

View more
  9 in total

1.  Detection of cavernous malformations after whole-brain radiotherapy in primitive neuroectodermal tumor patients-comparing susceptibility-weighted imaging and T2 gradient-echo sequences.

Authors:  Vadim Khasminsky; Michal Yalon; Gahl Greenberg; Galia Tsarfaty; Eli Atar; Chen Hoffmann
Journal:  Neuroradiology       Date:  2018-07-20       Impact factor: 2.804

Review 2.  Clinical Management of Cavernous Malformations.

Authors:  Kelly D Flemming
Journal:  Curr Cardiol Rep       Date:  2017-10-18       Impact factor: 2.931

3.  Assessment of cerebral microbleeds by susceptibility-weighted imaging in Alzheimer's disease patients: A neuroimaging biomarker of the disease.

Authors:  Gianvincenzo Sparacia; Francesco Agnello; Giuseppe La Tona; Alberto Iaia; Federico Midiri; Benedetta Sparacia
Journal:  Neuroradiol J       Date:  2017-05-02

4.  Multiple sclerosis: High prevalence of the 'central vein' sign in white matter lesions on susceptibility-weighted images.

Authors:  Gianvincenzo Sparacia; Francesco Agnello; Angelo Gambino; Martina Sciortino; Massimo Midiri
Journal:  Neuroradiol J       Date:  2018-03-22

5.  Complications of Radiotherapy and Radiosurgery in the Brain and Spine.

Authors:  G Barisano; S Bergamaschi; J Acharya; A Rajamohan; W Gibbs; P Kim; G Zada; E Chang; M Law
Journal:  Neurographics (2011)       Date:  2018-06

6.  Natural history of familial cerebral cavernous malformation syndrome in children: a multicenter cohort study.

Authors:  Ana Filipa Geraldo; Cesar Augusto P F Alves; Aysha Luis; Domenico Tortora; Joana Guimarães; Daisy Abreu; Sofia Reimão; Marco Pavanello; Patrizia de Marco; Marcello Scala; Valeria Capra; Rui Vaz; Andrea Rossi; Erin Simon Schwartz; Kshitij Mankad; Mariasavina Severino
Journal:  Neuroradiology       Date:  2022-10-06       Impact factor: 2.995

7.  High Prevalence of Spinal Cord Cavernous Malformations in the Familial Cerebral Cavernous Malformations Type 1 Cohort.

Authors:  M C Mabray; J Starcevich; J Hallstrom; M Robinson; M Bartlett; J Nelson; A Zafar; H Kim; L Morrison; B L Hart
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-28       Impact factor: 3.825

8.  Assessment of cerebral microbleeds by susceptibility-weighted imaging at 3T in patients with end-stage organ failure.

Authors:  Gianvincenzo Sparacia; Roberto Cannella; Vincenzina Lo Re; Angelo Gambino; Giuseppe Mamone; Roberto Miraglia
Journal:  Radiol Med       Date:  2018-02-17       Impact factor: 3.469

9.  Multiple sclerosis: prevalence of the 'central vein' sign in white matter lesions on gadolinium-enhanced susceptibility-weighted images.

Authors:  Gianvincenzo Sparacia; Francesco Agnello; Alberto Iaia; Aurelia Banco; Massimo Galia; Massimo Midiri
Journal:  Neuroradiol J       Date:  2021-04-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.